Lv51
880 积分 2025-04-25 加入
BCL6 as a therapeutic target for lymphoma
4小时前
已完结
Clinical significance of ‘double-hit’ and ‘double-expression’ lymphomas
3天前
已完结
Diffuse Large B-Cell Lymphoma/High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements: a study of 60 Cases
3天前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
3天前
已完结
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
5天前
已完结
The high-grade B-cell lymphomas: Double hit and more
7天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
12天前
已完结
HER2-targeted therapies beyond breast cancer — an update
12天前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
13天前
已完结
[Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy（2024 edition）]
14天前
已完结
皖公网安备34019202002308
